{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:40:50Z","timestamp":1789724450587,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001868","name":"NSC","doi-asserted-by":"publisher","award":["102-2320-B-007-011-MY2"],"award-info":[{"award-number":["102-2320-B-007-011-MY2"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MOST","award":["103-2221-E-007-032-MY2"],"award-info":[{"award-number":["103-2221-E-007-032-MY2"]}]},{"name":"Chang Gung Memorial Hospital\u2014National Tsing Hua University Joint Research","award":["104N2744E1"],"award-info":[{"award-number":["104N2744E1"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jconrel.2015.11.003","type":"journal-article","created":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T01:52:39Z","timestamp":1446861159000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis"],"prefix":"10.1016","volume":"221","author":[{"given":"Ts-Ting","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Chieh","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsaiyu","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.11.003_bb0005","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fernandez","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0015","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.25545","article-title":"Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice","volume":"55","author":"Sahin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mam.2007.09.002","article-title":"Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario","volume":"29","author":"Parola","year":"2008","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0025","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1053\/j.gastro.2008.07.065","article-title":"Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis","volume":"135","author":"Taura","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0030","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI66369","article-title":"Hepatic stellate cells in liver development, regeneration, and cancer","volume":"123","author":"Yin","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cld.2008.07.013","article-title":"Cytokines and renin-angiotensin system signaling in hepatic fibrosis","volume":"12","author":"Moreno","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0040","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/labinvest.2008.71","article-title":"Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury","volume":"88","author":"Borkham-Kamphorst","year":"2008","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2001-17556","article-title":"Matrix as a modulator of hepatic fibrogenesis","volume":"21","author":"Schuppan","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0050","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/hep.23144","article-title":"Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis","volume":"50","author":"Patsenker","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nrgastro.2013.227","article-title":"Liver: key role for alphav integrins in myofibroblasts in liver fibrosis","volume":"11","author":"Ray","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0060","doi-asserted-by":"crossref","first-page":"G425","DOI":"10.1152\/ajpgi.00050.2011","article-title":"Role of integrins in fibrosing liver diseases","volume":"301","author":"Patsenker","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0065","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2012.07.033","article-title":"HSC-specific inhibition of rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects","volume":"57","author":"Klein","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2005.06.015","article-title":"Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term","volume":"44","author":"Neef","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0075","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0080","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.26790","article-title":"Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha\/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis","volume":"53","author":"Wang","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/labinvest.2010.148","article-title":"Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis","volume":"91","author":"Hennenberg","year":"2011","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0095","first-page":"257","article-title":"Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo","volume":"58","author":"Hong","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2013.07.008","article-title":"STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib","volume":"46","author":"Deng","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jpba.2009.02.008","article-title":"Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice","volume":"49","author":"Blanchet","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1556-276X-7-91","article-title":"Antitumor activity of sorafenib-incorporated nanoparticles of dextran\/poly(dl-lactide-co-glycolide) block copolymer","volume":"7","author":"Kim do","year":"2012","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijpharm.2011.08.003","article-title":"Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat","volume":"419","author":"Wang","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/erm.09.15","article-title":"Current advances in research and clinical applications of PLGA-based nanotechnology","volume":"9","author":"Lu","year":"2009","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2004.04.026","article-title":"Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density","volume":"98","author":"Vila","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0135","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG\u2013PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0140","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejphar.2011.09.023","article-title":"Long circulating chitosan\/PEG blended PLGA nanoparticle for tumor drug delivery","volume":"670","author":"Parveen","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0145","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.biomaterials.2006.03.006","article-title":"The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly (lactide)\u2013tocopheryl polyethylene glycol succinate nanoparticles","volume":"27","author":"Zhang","year":"2006","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.11.003_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10404-012-1024-5","article-title":"The influence of size, shape and vessel geometry on nanoparticle distribution","volume":"14","author":"Tan","year":"2013","journal-title":"Microfluid. Nanofluid."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2172-13-42","article-title":"The peritoneal macrophage inflammatory profile in cirrhosis depends on the alcoholic or hepatitis C viral etiology and is related to ERK phosphorylation","volume":"13","author":"Tapia-Abellan","year":"2012","journal-title":"BMC Immunol."},{"key":"10.1016\/j.jconrel.2015.11.003_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.toxlet.2009.04.017","article-title":"The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles","volume":"189","author":"Cho","year":"2009","journal-title":"Toxicol. Lett."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915302273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915302273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T23:29:06Z","timestamp":1537226946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915302273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":32,"alternative-id":["S0168365915302273"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}